Welcome to our dedicated page for DBV Technologies S.A. SEC filings (Ticker: DBVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DBV Technologies S.A. filings document the disclosure record of a French late-stage biopharmaceutical issuer with American Depositary Shares listed under DBVT. The filings identify ordinary shares and ADSs, with each ADS representing five ordinary shares, and cover the company’s VIASKIN patch technology, epicutaneous immunotherapy approach, and food-allergy development programs.
Recent SEC materials include Form 8-K reports for operating results, business highlights, clinical-data releases for the Phase 3 VITESSE study, warrant-related financing events, and governance matters. Proxy materials describe shareholder meeting proposals, board and committee matters, executive compensation, and equity-award plans.
Artisan Partners, through several affiliated Delaware entities, reports beneficial ownership of 3,309,055 DBV Technologies S.A. American Depositary Shares, representing 7.0% of the class based on 47,134,173 shares outstanding as of 12/31/2025. The position is held for discretionary clients of Artisan Partners Limited Partnership.
Artisan reports no sole voting or dispositive power, with shared voting power over 2,976,900 shares and shared dispositive power over 3,309,055 shares. The firms state the securities were acquired and are held in the ordinary course of business, not to change or influence control of DBV Technologies.
DBV Technologies S.A. Chief Medical Officer Mohideen Pharis reported a small insider sale of company stock. On January 29, 2026, Pharis sold 534 ordinary shares of DBV Technologies at a price of $4.86 per share, primarily to satisfy withholding tax obligations linked to vesting restricted stock units. After this transaction, Pharis beneficially owned 144,995 ordinary shares, held directly. The filing also notes that DBV Technologies’ ordinary shares may be represented by American Depositary Shares, with each ADS currently representing five ordinary shares.
DBV Technologies S.A. reported that it issued a press release on January 16, 2026 announcing €166.7 million in gross proceeds from the full exercise of ABSA warrants and BS warrants that were issued in its March financing. This warrant exercise brings a substantial amount of new cash into the company. The press release, filed as Exhibit 99.1, provides further details on the transaction.
Baker Bros. Advisors and related entities report beneficial ownership of 25,586,190 ordinary shares of DBV Technologies S.A., equal to 9.99% of the class based on 254,000,000 ordinary shares outstanding as of January 12, 2026. All voting and dispositive power over these holdings is reported as sole, with no shared power.
The position includes ordinary shares plus pre-funded warrants and other warrants that can be exercised into additional ordinary shares, all subject to contractual beneficial ownership limits generally capped at 9.99%, with potential increases only after regulatory conditions and waiting periods. The filing also notes that on January 12, 2026, affiliated funds exercised certain warrants into long-dated pre-funded warrants expiring in 2035, and that director Michael Goller’s board-compensation warrants are treated as having pecuniary benefit for the Baker Bros. funds, not for him personally.
DBV Technologies S.A. insider filing shows major warrant restructuring by Baker Brothers–affiliated funds. On January 12, 2026, 667, L.P. and Baker Brothers Life Sciences, L.P. exercised 2,299,656 and 25,005,240 DBV Technologies BS Warrants at a strike price of EUR 1.5764, receiving an equal number of Second Pre-Funded Warrants. Each Second Pre-Funded Warrant is initially exercisable for 1.75 Ordinary Shares at an unpaid exercise price of EUR 0.01 per underlying share and may be exercised until April 7, 2035.
The Second Pre-Funded Warrants are subject to a “Second Pre-Funded Warrant Beneficial Ownership Limitation,” generally capping beneficial ownership at 9.99% of DBV’s outstanding Ordinary Shares, with potential increases up to 19.99% of shares and 24.99% of voting rights subject to regulatory conditions and a 61‑day waiting period. The transactions and resulting indirect pecuniary interests are reported for entities including 667, L.P., Baker Brothers Life Sciences, L.P., Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, and individuals Julian C. Baker and Felix J. Baker, who disclaim beneficial ownership except to the extent of their pecuniary interests.
Janus Henderson Group plc filed an amended Schedule 13G reporting beneficial ownership of 20,469,392 shares of DBV Technologies S.A. common stock, representing 8.8% of the class as of the event date 12/31/2025. The firm reports no sole voting or dispositive power, but shared voting and shared dispositive power over all of these shares.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of DBV Technologies. It also notes that interests of any single managed portfolio do not exceed 5% of the class of securities.
DBV Technologies S.A. received an updated Schedule 13D/A from a group of French public investment entities led by Bpifrance detailing their ownership of the company’s ordinary shares.
As of January 7, 2026, Bpifrance Participations directly holds 10,672,462 ordinary shares, or 4.6% of DBV Technologies’ outstanding ordinary shares, while Innobio directly holds 226,133 shares, or 0.1%. Through its ownership structure, Bpifrance, together with EPIC Bpifrance and Caisse des Depots, may be deemed to beneficially own 10,898,595 shares, or 4.7%, based on 232,047,938 ordinary shares outstanding as of December 31, 2025.
On January 5, 2026, Bpifrance Participations sold 86,777 ordinary shares in open-market transactions at a weighted average price of EUR3.02 per share. Due to these sales and exercises of warrants by various holders, Bpifrance Participations’ beneficial ownership fell below 5%, and this Amendment No. 10 is designated as a final, “exit” Schedule 13D filing for the reporting group.
DBV Technologies S.A. reported that it has issued a press release announcing positive topline results from its Phase 3 VITESSE trial of the VIASKIN Peanut Patch in peanut allergic children aged 4-7 years. This current report on Form 8-K attaches the full press release as an exhibit and incorporates it by reference.
The announcement marks a late-stage clinical milestone for the company’s peanut allergy program in young children. By formally furnishing the press release through the SEC, DBV signals that the Phase 3 VITESSE outcome for the VIASKIN Peanut Patch in 4- to 7-year-olds is an important development for its pipeline.
DBV Technologies S.A. reported insider activity by Chief Medical Officer Mohideen Pharis involving new equity awards and small share sales. On November 21, 2025, he was granted 253,000 stock options with a $2.90 exercise price, expiring November 21, 2035, and 44,000 RSUs, with both awards vesting in four equal annual installments starting November 21, 2026, subject to continued service. He sold a total of 8,120 ordinary shares on November 20–21, 2025 at prices around $2.8800 and $2.7700 per share. After these transactions, he directly holds 145,529 ordinary shares. The company notes that some shares were sold to satisfy withholding tax obligations upon RSU vesting and that each American Depositary Share represents five ordinary shares.
DBV Technologies S.A. (DBVT) reported a Form 4 for its Chief Financial Officer, Virginie Boucinha, reflecting new equity compensation granted on 11/21/2025. She acquired 32,000 ordinary shares at a price of $0, representing ordinary shares underlying a restricted stock unit (RSU) award, bringing her directly held ordinary shares to 70,000. She also received an employee stock option for 192,000 ordinary shares with an exercise price of $2.9 and an expiration date of 11/21/2035. Both the RSUs and the option vest in four equal annual installments starting on November 21, 2026, contingent on her continued service with the company.